DOI: https://doi.org/10.25305/unj.126654

Heterogeneity of oligoastrocytoma: morphology, surgery, and survival in the series of 163 patients. Retrospective study

Valentyn M. Kliuchka, Artem V. Rozumenko, Volodymyr D. Rozumenko, Vіra M. Semenova, Tatyana A. Malysheva

Abstract


Introduction. The current approach to oligoastrocytoma (OA) treatment includes surgery taking into account the anatomical and physiological accessibility using various radio- and chemotherapy protocols. Nevertheless, it should be recognized that influence of OA histological structure on the surgery of these tumors has not conclusively established.

Objective. To improve diagnostic and surgical tactics in oligoastrocytoma by comparing determined clinical-histological patterns.

Materials and methods. Retrospective clinical-morphological comparison and analysis of treatment results in 163 patients with OA were performed taking into account histological structure. OAII (WHO) was diagnosed in 32 patients (19.6 %), 131 patients (80.4 %) developed OAIII (WHO).

Results. In 52 OA cases (32 %) oligodendroglial component (oOA) prevailed, in 48 OA cases (29 %) astrocytic component (aOA) prevailed, in 63 OA cases (39 %) there was relatively equal cells distribution of both components (оаОА). The surgical treatment of 163 patients included the following: gross total removal, 60 patients (31.4 %); subtotal removal, 98 patients (60.2 %); and partial removal, 4 patients (2.4 %). A total of 106 (65.0 %) patients presented with Karnofsky Performance Status Scale (KPS) ≥ 80. One hundred and fifty-three patients (93.9 %) experienced postsurgery KPS ≥ 80. There was no perioperative death. All 163 patients received radiation therapy and 87 patients (53.4 %) received chemotherapy as well. A significant difference (p< 0.05) in overall survival (OS) was found between surgery results of OA histological groups. Clinical and MRI/CT findings significantly correlated with histological types of OA as well as results of treatment: the overall survival in patients with oOA was 100.5 ± 4.6 months, aOA — 48.2 ± 4.5 months, oaOA — 76.6 ± 4.9 months, averaging 49.9 ± 2.4 months.

Conclusions. Diagnosing, surgery, and survival of OA are determined by the uniqueness of the histological structure of these tumors, the interaction of their components, topography and expansion direction. The key to successful results is a differential approach to planning diagnostic tactics, method of removal and management in late post-op period.


Keywords


oligoastrocytoma; histology; surgery; survival

Full Text:

PDF

References


1. Cooper E. The relation of oligocytes and astrocytes in cerebral tumors. The Journal of Pathology and Bacteriology. 1935 Sept; 41(2):259-266. [CrossRef]

2. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013 Nov;15 Suppl 2:ii1-56. [CrossRef] [PubMed] [PubMed Central]

3. Kim SI, Lee Y, Won JK, Park CK, Choi SH, Park SH. Reclassification of Mixed Oligoastrocytic Tumors Using a Genetically Integrated Diagnostic Approach. J Pathol Transl Med. 2018 Jan;52(1):28-36. [CrossRef] [PubMed] [PubMed Central]

4. Wesseling P, van den Bent M, Perry A. Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015 Jun;129(6):809-27. [CrossRef] [PubMed] [PubMed Central]

5. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun;131(6):803-20. [CrossRef] [PubMed]

6. Huse JT, Diamond EL, Wang L, Rosenblum MK. Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true “oligoastrocytoma”? Acta Neuropathol. 2015 Jan;129(1):151-3. [CrossRef] [PubMed]

7. Cryan JB, Haidar S, Ramkissoon LA, Bi WL, Knoff DS, Schultz N, Abedalthagafi M, Brown L, Wen PY, Reardon DA, Dunn IF, Folkerth RD, Santagata S, Lindeman NI, Ligon AH, Beroukhim R, Hornick JL, Alexander BM, Ligon KL, Ramkissoon SH. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget. 2014 Sep 30;5(18):8083-92. [PubMed] [PubMed Central]

8. Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP, Colman H. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurg Focus. 2015 Mar;38(3):E2. [CrossRef] [PubMed]

9. Michaud K, de Tayrac M, D’Astous M, Duval C, Paquet C, Samassekou O, Gould PV, Saikali S. Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines. PLoS One. 2016 Dec 28;11(12):e0168728. [CrossRef] [PubMed] [PubMed Central]

10. Abrigo JM, Fountain DM, Provenzale JM, Law EK, Kwong JS, Hart MG, Tam WWS. Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation. Cochrane Database Syst Rev. 2018 Jan 22;1:CD011551. [CrossRef] [PubMed]

11. Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, Veelken J, Schramm J, Weller M, Wiestler OD, Louis DN, von Deimling A. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol. 2002 Jul;161(1):313-9. [PubMed] [PubMed Central]

12. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013 Jan 20;31(3):337-43. [CrossRef] [PubMed] [PubMed Central]

13. Shaw EG, Scheithauer BW, O’Fallon JR, Davis DH. Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery. 1994 Apr;34(4):577-82; discussion 582. [PubMed]

14. Alonso D, Matallanas M, Riveros-Pйrez A, Pйrez-Payo M, Blanco S. Prognostic and predictive factors in high-grade gliomas. Experience at our institution. Neurocirugia (Astur). 2017 Nov - Dec;28(6):276-283. Spanish. [CrossRef] [PubMed]

15. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990 Jul;8(7):1277-80. [PubMed]

16. Bai HX, Zou Y, Lee AM, Tang X, Zhang P, Yang L. Does morphological assessment have a role in classifying oligoastrocytoma as ‘oligodendroglial’ versus ‘astrocytic’? Histopathology. 2016 Jun;68(7):1114-5. [CrossRef] [PubMed]

17. Naugle DK, Duncan TD, Grice GP. Oligoastrocytoma. Radiographics. 2004 Mar-Apr;24(2):598-600. [PubMed]

18. Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, Harter PN, Jeibmann A, von Deimling A. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol. 2011 Feb;121(2):241-52. [CrossRef] [PubMed]

19. Hewer E, Vajtai I, Dettmer MS, Berezowska S, Vassella E. Combined ATRX/IDH1 immunohistochemistry predicts genotype of oligoastrocytomas. Histopathology. 2016 Jan;68(2):272-8. [CrossRef] [PubMed]

20. Vogelbaum MA, Hu C, Peereboom DM, Macdonald DR, Giannini C, Suh JH, Jenkins RB, Laack NN, Brachman DG, Shrieve DC, Souhami L, Mehta MP. Phase II trial of prerradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. J Neurooncol. 2015 Sep;124(3):413-20. [CrossRef] [PubMed] [PubMed Central]

21. Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldбn GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Panageas KS. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011 Jun;13(6):649-59. [CrossRef] [PubMed] [PubMed Central]


GOST Style Citations






Copyright (c) 2018 Valentyn M. Kliuchka, Artem V. Rozumenko, Volodymyr D. Rozumenko, Vіra M. Semenova, Tatyana A. Malysheva

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.